Abstract
A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have